Table 5. Survival Benefit for Urban Patients, Compared with Rural Patients, According to Menopausal Status.
| HR | 95% CI | P | |
|---|---|---|---|
| Pre-menopausal | |||
| OS | 0.4047 | 0.20–0.81 | < 0.001 |
| MFS | 0.79 | 0.49–1.3 | 0.34 |
| RFS | 0.43 | 0.17–1.1 | 0.06 |
| Survival after metastasis | 0.34 | 0.16–0.72 | 0.005 |
| PFS | 0.74 | 0.48–1.1 | 0.17 |
| Post-menopausal | |||
| OS | 0.62 | 0.29–1.3 | 0.22 |
| MFS | 0.54 | 0.30–0.97 | 0.04 |
| RFS | 1.3 | 0.3–5.6 | 0.73 |
| Survival after metastasis | 1 | 0.42–2.6 | 0.93 |
| PFS | 0.67 | 0.38–1.2 | 0.18 |
CI = confidence interval, HR = hazard ratio, MFS = metastasis-free survival, OS = overall survival, PFS = progression-free survival, RFS = relapse-free survival.